Atrium Therapeutics

siRNA
#Atrium Therapeutics #Cardiovascular disease #RNA #Start-ups

New launch Atrium will focus on RNA medicines for cardiomyopathy

Atrium Therapeutics has launched as a newly independent, publicly traded company developing RNA therapeutics for people living with rare, life-threatening genetic cardiomyopathies.   Atrium Therapeutics was established in connection with Avidity Biosciences’ acquisition by Novartis. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO), and begins operations… Read More

#Business & Investment #News #Start-up Zone